The German research products firm attributed the higher revenues to organic growth, as well as the impact of recent acquisitions such as TGR Biosciences.
The firm will use the agreement to access alternative non-dilutive means of financing of its growth plans.
The company, which has just changed its name from Sygnis, has now completed the integration of several recent acquisitions including TGR Biosciences.
The company anticipates 2018 revenues in the range of €11 million to €12 million, excluding the impact of recently acquired TGR Biosciences.
TGR's proprietary protein capturing technology is expected to complement Sygnis' range of immunology, genomic, and proteomic products and services.
The company had intended to raise up to €6.6 million through the placement to help fund its planned acquisition of TGR Biosciences.
Sygnis said that TGR is profitable and has a complementary product portfolio that includes protein capture technology.
23andMe and Airbnb have partnered to offer "heritage travel," according to Venture Beat.
China may include regulations protecting genes and embryos in its update of its civil code, Nature News reports.
In Nature this week: exome sequence analysis of individuals with type 2 diabetes, genomic prediction of maize yield across environments, and more.
NPR reports on efforts to engineer bacteriophages to destroy antibiotic-resistance bacteria.